Department of Anaesthesia, University of Toronto, Toronto, Canada.
Department of Anaesthesia, St. Michael's Hospital, University of Toronto, Toronto, Canada.
Br J Anaesth. 2017 Feb;118(2):167-181. doi: 10.1093/bja/aew411.
Dexmedetomidine has been proposed as a perineural local anaesthetic (LA) adjunct to prolong peripheral nerve block duration; however, results from our previous meta-analysis in the setting of brachial plexus block (BPB) did not support its use. Many additional randomized trials have since been published. We thus conducted an updated meta-analysis.
Randomized trials investigating the addition of dexmedetomidine to LA compared with LA alone (Control) in BPB for upper extremity surgery were sought. Sensory and motor block duration, onset times, duration of analgesia, analgesic consumption, pain severity, patient satisfaction, and dexmedetomidine-related side-effects were analysed using random-effects modeling. We used ratio-of-means (lower confidence interval [point estimate]) for continuous outcomes.
We identified 32 trials (2007 patients), and found that dexmedetomidine prolonged sensory block (at least 57%, P < 0.0001), motor block (at least 58%, P < 0.0001), and analgesia (at least 63%, P < 0.0001) duration. Dexmedetomidine expedited onset for both sensory (at least 40%, P < 0.0001) and motor (at least 39%, P < 0.0001) blocks. Dexmedetomidine also reduced postoperative oral morphine consumption by 10.2mg [-15.3, -5.2] (P < 0.0001), improved pain control, and enhanced satisfaction. In contrast, dexmedetomidine increased odds of bradycardia (3.3 [0.8, 13.5](P = 0.0002)), and hypotension (5.4 [2.7, 11.0] (P < 0.0001)). A 50-60µg dexmedetomidine dose maximized sensory block duration while minimizing haemodynamic side-effects. No patients experienced any neurologic sequelae. Evidence quality for sensory block was high according to the GRADE system.
New evidence now indicates that perineural dexmedetomidine improves BPB onset, quality, and analgesia. However, these benefits should be weighed against increased risks of motor block prolongation and transient bradycardia and hypotension.
右美托咪定被提议作为一种局部麻醉药(LA)的辅助药物,以延长周围神经阻滞的持续时间;然而,我们之前在臂丛神经阻滞(BPB)中的荟萃分析结果并不支持其使用。此后,许多额外的随机试验已经发表。因此,我们进行了一项更新的荟萃分析。
我们寻找了将右美托咪定加入到用于上肢手术的 LA 中与单独使用 LA(对照组)相比的随机试验。使用随机效应模型分析感觉和运动阻滞持续时间、起效时间、镇痛持续时间、镇痛药物消耗、疼痛严重程度、患者满意度和右美托咪定相关的副作用。我们使用比值(置信区间[点估计]下限)来表示连续结果。
我们确定了 32 项试验(2007 名患者),发现右美托咪定延长了感觉阻滞(至少 57%,P<0.0001)、运动阻滞(至少 58%,P<0.0001)和镇痛(至少 63%,P<0.0001)持续时间。右美托咪定还加速了感觉(至少 40%,P<0.0001)和运动(至少 39%,P<0.0001)阻滞的起效时间。右美托咪定还减少了术后口服吗啡的消耗量 10.2mg[-15.3,-5.2](P<0.0001),改善了疼痛控制,并提高了满意度。相比之下,右美托咪定增加了心动过缓的几率(3.3[0.8,13.5](P=0.0002))和低血压(5.4[2.7,11.0](P<0.0001))。50-60μg 右美托咪定剂量最大限度地延长了感觉阻滞持续时间,同时最小化了血液动力学副作用。没有患者出现任何神经后遗症。根据 GRADE 系统,感觉阻滞的证据质量为高。
新的证据表明,周围神经阻滞中的右美托咪定可以改善 BPB 的起效时间、质量和镇痛效果。然而,这些益处应该与运动阻滞延长和短暂性心动过缓和低血压的风险相权衡。